We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Croda International Plc | CRDA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 27.00 | 0.56% | 4,876.00 | 16:35:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4,810.00 | 4,810.00 | 4,941.00 | 4,876.00 | 4,849.00 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 23/12/2021 15:48 by philanderer Croda: Vaccine boost offsets industrial saleThere was some disappointment at the decision of chemicals specialist Croda (CRDA) to sell its bio-based industrial business, but the stock remains well ahead this year thanks to its vaccine exposure, according to Hargreaves Lansdown. The group reported the sale of its bio-based industrial business to US firm Cargill Velocity for £778m following a review of this part of the business. The price tag has, however, disappointed some investors, as the shares eased 0.4% to £99.42. Analyst Susannah Streeter said it was still one of the FTSE 100’s best performers in 2021, up 48% over the year thanks to strong first-half results and full-year profits forecast to beat earlier expectations. ‘The extent to which Croda is benefiting from the ongoing vaccine boom has become clear over recent months and it’s down to its investment in innovative technologies,’ she said. ‘It supplies lipid nanoparticles for Pfizer’s mRNA technology and given the demand for booster jabs, that area of life sciences is bounding along.’ Streeter said even when vaccine demand wanes there will still be demand for ‘a broader range of use of its products in medical treatments like oncology’. ‘Recovery in consumer markets has also helped its personal care sector which focuses on ingredients for skin, hair, and cosmetic products and the focus on sustainability should help drive sales among an increasingly eco-conscious customer base,’ said Streeter. citywire.com |
Posted at 14/12/2020 01:54 by davidosh Just to mention that the Xmas MelloMonday special guest may mention Croda and I think shareholders and potential investors will appreciate his thoughts. There is an interview tonight with Keith Ashworth Lord who is a highly respected fund manager and well worth listening to. Keith's fund Castlefield are of course one of the larger shareholders in Croda and I think it is one of their top ten positions.The Mello Monday event starts at 6pm The full programme is available on the website. Also of interest may be the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four companies are a Buy Avoid Sell or Hold at this current juncture in the markets. All investors welcome and if you use the code MMTADVFN50 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular. |
Posted at 27/7/2020 14:50 by lyndon b I think the only explanation is the dividend (and it being maintained, while most other companies have not held it in place). Big investors are holding for that reason and getting a capital gain to boot.If you look at the financials of this company on their own (profit down 10%), some margin erosion in their high end personal care segment, some business segment links to automotive/oil industry etc etc, then the share price gain/ALL TIME HIGH makes zero sense.Based on current/future trading against historical, then £50/share makes better sense, though as we all know SP's rarely make sense. |
Posted at 23/7/2013 09:11 by miata Interim dividend increased 8.4% to 29.0p (2012: 26.75p).The company has rewarded investors with a sharp rise in its share price in the last five years - up more than +550%. For the last six months, operating profit climbs +4.2% to £139.1m while profit before tax climbs +6.3% to £133.1m. In terms of second quarter performance, operating profit climbs +4.4% to £71.1m with profit before tax up +6.1% to £68.0m. Consumer Care sales driven by double digit growth across Personal Care and Health Care in Europe says Croda. "Although the challenging trading environment," says chairman Martin Flower, "has inevitably held back certain parts of the business, our leading positions in niche markets and steadfast commitment to innovation are reflected in improved profits and margins in all three business divisions." |
Posted at 16/4/2013 09:19 by miata If only the market took as much notice of Berenberg as it does of Goldmans or Credit Suisse.Croda International's stock had its "buy" rating reiterated by investment analysts at Berenberg Bank in a note issued to investors on Tuesday, Stock Ratings Network reports. They currently have a GBX 3,200 ($49.09) target price on the stock, up from their previous target price of GBX 2,700 ($41.42). Croda International opened at 2581.00 on Tuesday. Croda International has a 52-week low of GBX 1998.0 and a 52-week high of GBX 2846.0. The stock's 50-day moving average is currently GBX 2399.89. The company's market cap is £3.465 billion. Several other analysts have also recently commented on the stock. Analysts at Credit Suisse reiterated a "neutral" rating on shares of Croda International in a research note to investors on Thursday, April 11th. They now have a GBX 2,599.60 ($39.88) price target on the stock. Separately, analysts at Deutsche Bank raised their price target on shares of Croda International from GBX 2,349.64 ($36.05) to GBX 2,399.63 ($36.82) in a research note to investors on Wednesday, April 10th. They now have a "hold" rating on the stock. Finally, analysts at Canaccord Genuity reiterated a "sell" rating on shares of Croda International in a research note to investors on Thursday, April 4th. They now have a GBX 1,881.53 ($28.87) price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of "Hold" and an average target price of GBX 2,548.06 ($39.09). |
Posted at 18/3/2013 16:56 by miata Several brokers commented :Analysts at Bank of America upped their price target on shares of Croda International (LON: CRDA) from $37.76 (2500 GBX) to $43.81 (2900 GBX) in a research report issued to clients and investors on Friday. The firm currently has a "buy" rating on the stock. Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley raised their price target on shares of Croda International from $40.32 to $42.56 in a research note to investors on Monday, March 11th. They now have an "overweight" rating on the stock. Separately, analysts at Credit Suisse reiterated a "neutral" rating on shares of Croda International in a research note to investors on Tuesday, March 12th. They now have a $38.83 price target on the stock. Finally, analysts at Mirabaud Securities raised their price target on shares of Croda International from $40.32 to $42.56 in a research note to investors on Friday, March 8th. They now have an "overweight" rating on the stock. Croda International (LON: CRDA) opened at 2666.00 on Friday. Croda International has a 52-week low of GBX 1998.0499 and a 52-week high of GBX 2705.00. The stock's 50-day moving average is currently GBX 2399.89. The company's market cap is £3.588 billion. |
Posted at 09/10/2012 11:49 by miata "Simple profit-taking could be one reason for Croda's decline. Even with the recent fall, this share has gained 28% since the start of the year. Loyal investors will not be worrying too much either, as the price has advanced six-fold since late 2008 and 11-fold since early 2003. July's half-year results showed both earnings and the dividend up 8%." |
Posted at 23/2/2012 06:02 by broadwood This is likely to get into the FTSE at the March review which means trackers will have to buy - so even with the strong rise. there could be more to come.Croda International Croda makes the building blocks for products such as sun-creams and fertilisers, as well as industrial applications. Full-year numbers were ahead of consensus expectations in terms of pre-tax profits, earnings per share and dividend. This was despite a challenging environment in its European industrial specialities unit in the final quarter of last year. In the 12 months to December, pre-tax profits rose 25.9pc to £242.2m, beating expectations by 1.8pc. This was on sales that were 6.6pc ahead at £1.068bn. The final dividend was raised by almost 20pc to 30.25p a share, bringing the total payment for the year to 55p an increase of 57.1pc. The final payment will be made on June 1. The strong rise in the payment reflects Croda's new dividend policy to pay out between 40pc and 50pc of annual earnings. The dividend is in addition to a £50m share buyback completed during the year. Croda is also a strong candidate for entry into the FTSE 100 when the reshuffle is unveiled next month. The company has proved over recent years that it is able to pass on the cost of rising feedstock prices to customers. This role as a price-setter rather than a price-taker is very important for profits. Management expects input costs to continue to rise, but it is important to note that the majority of its feedstocks do not come from oil about 75pc are from renewable sources such as rape-seed oil and palm oil. The company is split into two units consumer care and industrial specialities. Growth at its consumer unit was strong, with sales up 11.2pc in 2011, with industrial specialities growing by 1.8pc. Obviously, the industrial operations are leveraged to any upturn. The European industrial operations had a difficult fourth quarter, with total sales at the unit actually falling by 4.8pc. Sales at consumer care, however, rose by more than 9pc in the quarter. The new management has also introduced some new financial targets. For consumer care, Croda has upped its medium-term target for a return on sales to 25pc from 20pc. In industrials, the return on sales target is upped from 15pc to 20pc. Croda has been extremely rewarding for investors over the past few years, as its strategy of focusing on low-volume, high-margin speciality chemicals boosted profitability. This means the shares are now trading at all-time highs. They are up 21pc since they were last tipped on December 21 last year, compared with a FTSE 100 up 10pc, and an impressive 445pc since they were tipped at 389¾p on December 9, 2008. The shares are currently trading on a December 2012 earnings multiple of 15.6 times, falling to 15.1 in 2013, and are yielding a prospective 2.7pc, rising to 3pc in 2013. Questor suspects the shares may pause for breath now after such a strong run, so rates the shares a hold. However, any investors that bought in at a low level should top-slice this investment and sell half. |
Posted at 28/5/2009 11:34 by limit up the reason i started to look at it,as several houses had upgraded the stock to a price target of £7.00 with all the reasons behind it,also the kiss of death the investors con featured the stock 3 weeks ago,it has fallen since the puff up.it does look cheap ,i have not bought any yet ,perhaps arund the £5.00 levell,my thoughts,as i am looking for a correction in the mkts.i was wondering whether they may have a rights issue to help clear the debt?? |
Posted at 11/2/2009 09:28 by fast investor From todays Daily Telegraph..City Comment: An opportunity missed to grill bankers in detail about their role in crisis; Landlords fear Stylo deal sets precedent; Not a lot to offer Grainger investors Feature Column by Sir Nigel Rudd, chairman of BAA: When the new economic dawn comes, we must be the first to see the sun Questor: Petrofac Hold; Croda - Buy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
